AZ 10397767
Tocris Bioscience, part of Bio-Techne | Catalog # 5872
Potent CXCR2 antagonist
Key Product Details
Description
Potent CXCR2 antagonist
Product Description
AZ 10397767 is a potent CXCR2 antagonist (IC50 = 1 nM); attenuates oxaliplatin-induced NF-κB activation, increases oxaliplatin cytotoxicity, and potentiates oxaliplatin-induced apoptosis in AIPC cells. Reduces the numbers of neutrophils infiltrating into tumors in both in vitro and in vivo models and delayed tumor growth. Orally bioavailable.Product Specifications
Molecular Weight
400.88
Formula
C15H14ClFN4O2S2
Storage
Store at -20°C
Purity
≥98% (HPLC)
Chemical Name
5-[[(3-Chloro-2-fluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one
CAS Number
333742-63-5
PubChem ID
11858154
InChI Key
KHTUORKUWBDRBX-SSDOTTSWSA-N
SMILES
C[C@@H](NC1=C2SC(NC2=NC(SCC3=C(C(Cl)=CC=C3)F)=N1)=O)CO
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Solubility
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 40.09 | 100 |
Preparing Stock Solutions
for AZ 10397767
The following data is based on the product molecular weight 400.88
Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.49 mL | 12.47 mL | 24.95 mL |
| 5 mM | 0.50 mL | 2.49 mL | 4.99 mL |
| 10 mM | 0.25 mL | 1.25 mL | 2.49 mL |
| 50 mM | 0.05 mL | 0.25 mL | 0.50 mL |
Calculators
Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Background References
References are publications that support the biological activity of the product.
- Walters Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg.Med.Chem.Lett. 2008 PMID: 18240390
- Tazzyman Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int.J.Cancer 2011 PMID: 21328342
- Wilson Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxalip. through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J.Pharmacol.Exp.Ther. 2008 PMID: 18780829
Product Specific Notices for AZ 10397767
For research use only
Loading...
Loading...